NCT05465863View on ClinicalTrials.gov

Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases

NACompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

February 1, 2022

Study Completion Date

March 1, 2022

Conditions
Chronic Kidney Disease 5DChronic Kidney Disease 5T
Interventions
BIOLOGICAL

SARS-CoV-2 mRNA BNT162b2 vaccine (Pfizer-BioNTech®)

When permitted by local guidelines, children and adolescents who were over 12 years old were notified of vaccine eligibility and encouraged to schedule an appointment

Trial Locations (6)

34098

Istanbul University-Cerrahpasa, Istanbul

Unknown

Istanbul University, Istanbul School of Medicine, Istanbul

Istinye University, School of Medicine, Istanbul

Marmara University, School of Medicine, Istanbul

Medeniyet University, School of Medicine, Istanbul

Memorial Hospital, Istanbul

All Listed Sponsors
lead

Istanbul University - Cerrahpasa

OTHER

NCT05465863 - Humoral and Cellular İmmune Response to SARS-CoV-2 mRNA BNT162b2 Vaccine in Children With Chronic Kidney Diseases | Biotech Hunter | Biotech Hunter